---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-086039"
form_type: "8-K"
ticker: "VKTX"
cik: "0001607678"
company_name: "Viking Therapeutics, Inc."
filed_at: "2024-07-24T23:59:59+00:00"
generated_at: "2026-05-31T17:00:47.019920+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Viking advances VK2735 to Phase 3 for obesity; Q2 net loss $22.3M

## Summary
- VK2735 to advance to Phase 3 after positive VENTURE study; End-of-Phase 2 meeting with FDA planned for 2H24.
- Oral VK2735 Phase 2 trial in obesity expected to start in 4Q24; 28-day weight loss up to 5.3% from baseline.
- VK2809 met secondary endpoints in NASH/fibrosis; NASH resolution rates 63-75% vs 29% placebo; End-of-Phase 2 meeting 4Q24.
- Q2 net loss $22.3M ($0.20/share) vs $19.2M ($0.19) year ago; R&D expenses rose to $23.8M.
- Cash and investments $942M at June 30, 2024, up from $362M at year-end 2023.

## SEC filing metadata
- accession: 0000950170-24-086039
- form_type: 8-K
- ticker: VKTX
- cik: 0001607678
- company_name: Viking Therapeutics, Inc.
- filed_at: 2024-07-24T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1607678/000095017024086039/0000950170-24-086039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1607678/000095017024086039/vktx-20240724.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-086039
- JSON: https://secwatch.observer/filing/0000950170-24-086039.json
- Plain text: https://secwatch.observer/filing/0000950170-24-086039.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.